Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

N/ACompletedNCT05419349

Fujian Medical University Union Hospital1,819 enrolled

Overview

This study have two aims, the first is to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database the second is to provide a more accurate staging for Siewert type II AEG patients.

Study Type

OBSERVATIONAL

Enrollment

1,819

Conditions

Adenocarcinoma of the Esophagogastric Junction

Interventions

esophagogastric junction cancer surgeryPROCEDURE

esophagogastric junction cancer surgery

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed T1-4aN0-3M0 stage after surgery after a pathological examination of the LNs.

Locations (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Outcomes

Primary Outcomes

Overall survival

the time from disease diagnosis to death from any cause

Time frame: 5-year overall survival

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.